A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

Table 2 Treatment differences in change from baseline in number of CSBMs/wk for wk 1-4 (ITT population)

Timeperiod		Tegaserod 6mg b.i.d.n = 304	Placebon = 303
wk 1-4	n	303	303
	Mean (SD)	1.38 (1.759)	0.89 (1.444)
	Adjusted mean1	1.39	0.91
	Median	0.75	0.25
	Min, max	-2.0, 9.0	-1.5, 7.5
	Tegaserod-placebo	0.48
	(95% CI)2	(0.23, 0.73)
	P value3	0.0002
wk 1	Tegaserod–placebo	0.34
	(95% CI)2	(0.05, 0.64)
	P value3	0.0226
wk 2	Tegaserod-placebo	0.54
	(95% CI)2	(0.24, 0.84)
	P value3	0.0004
wk 3	Tegaserod–placebo	0.57
	(95% CI)2	(0.27, 0.86)
	P value3	0.0002
wk 4	Tegaserod–placebo	0.47
	(95% CI)2	(0.17, 0.77)
	P value3	0.002

CSBM: complete spontaneous bowel movement; SD: standard deviation; CI: confidence interval. Change from baseline (cfb) = post-baseline–baseline. A positive cfb indicates an increase in the number of CSBMs/wk.

¹Adjusted mean cfb. Calculated from least square mean estimate of repeated measures analysis.

²Treatment difference (> 0 favors tegaserod).

³Repeated measures model: cfb in number of CSBMs/wk = treatment (patient) + week + center + baseline + baseline *week + treatment *week.